Effect of recombinant feline interferon-ω alone and in combination with chemotherapeutic agents on putative tumour-initiating cells and daughter cells derived from canine and feline mammary tumours

Veterinary and Comparative Oncology

Volumn 7, Issue 4, 2009, Pages 222-229

  Penzo, C ^a   Ross, M ^a   Muirhead, R ^a   Else, R ^a   Argyle, D J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Chemotherapy; Interferon; Mammary tumours; Small animal; Stem cells; Tumour biology

Indexed keywords

ANTINEOPLASTIC AGENT; INTERFERON; INTERFERON OMEGA 1; RECOMBINANT PROTEIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; CAT; CAT DISEASE; CELL CULTURE; DOG; DOG DISEASE; DOSE RESPONSE; DRUG SCREENING; EXPERIMENTAL NEOPLASM; FEMALE; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; CAT DISEASES; CATS; CELLS, CULTURED; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; INTERFERON TYPE I; MAMMARY NEOPLASMS, ANIMAL; RECOMBINANT PROTEINS;

ANIMALIA; FELIDAE;

EID: 70450079236     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2009.00192.x     Document Type: Article

References (31)

1. Lana SE, Rutteman GR, Withrow SJ, Withrow SJ, Vail MD. Small Animal Clinical Oncology 2007, 619-636. In:, 4th edn., and, eds.,, St Louis, MO, Saunders Elsevier
2. Karayannopoulou M, Kaldrymidou E, Constantinidis TC, Dessiris A. Adjuvant post-operative chemotherapy in bitches with mammary cancer. Journal of Veterinary Medicine: Series A. 2001, 48:85-96.
3. Morris JS, Dobson JM, Bostock DE. Use of tamoxifen in the control of canine mammary neoplasia. The Veterinary Record 1993, 133:539-542.
4. Novosad CA, Bergman PJ, O'Brien MG, McKnight JA, Charney SC, Selting KA, Graham JC, Correa SS, Rosenberg MP, Gieger TL. Retrospective evaluation of adjunctive doxorubicin for the treatment of feline mammary gland adenocarcinoma: 67 cases. Journal of The American Animal Hospital Association 2006, 42:110-120.
5. Argyle DJ, Blacking T. From viruses to cancer stem cells: dissecting the pathways to malignancy. The Veterinary Journal 2008, 177:311-323.
6. Norval M, Maingav J, Else RW. Characteristics of a feline mammary carcinoma cell line. Research in Veterinary Science 1985, 39:157-164.
7. Else RW, Norval M, Neill WA. The characteristics of a canine mammary carcinoma cell line, REM 134. British Journal of Cancer 1982, 46:675-681.
8. Penzo C, Else R, Muirhead R, Ross R, Argyle DJ. Identification and analysis of cancer stem cells from canine and feline mammary tumours. 2008, Abstract in:, Copenaghen, Denmark, 28, February-1, March,,
9. Nicolini A, Carpi A. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial. Biomedicine & Pharmacotherapy 2005, 59:253-263.
10. Wadler S, Schwartz EL. New advances in interferon therapy of cancer. The Oncologist 1997, 2:254-267.
11. de Mari K, Maynard L, Eun HM, Lebreux B. Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled field trial. Veterinary Record 2003, 152:105-108.
12. de Mari K, Maynard L, Sanquer A, Lebreux B, Eun HM. Therapeutic effects of recombinant feline interferon-omega on feline leukemia virus (FeLV)-infected and FeLV/feline immunodeficiency virus (FIV)-coinfected symptomatic cats. Journal of Veterinary Internal Medicine 2004, 18:477-482.
13. Tateyama S, Priosoeryanto BP, Yamaguchi R, Uchida K, Ogiwara K, Suchiya AT. In vitro growth inhibition activities of recombinant interferon on all lines derived from canine tumours. Research in Veterinary Science 1995, 59:275-277.
14. Priosoeryanto BP, Tateyama S, Yamaguchi R, Uchida K. Antiproliferation and colony-forming inhibition activities of recombinant feline interferon (rFeIFN) on various cells in vitro. Canadian Journal of Veterinary Research 1995, 59:67-69.
15. Hampel V, Schwartz B, Kempf C, Kostlin R, Schillinger U, Kuchenhoff H, Fenske N, Brill T, Hirschberger J. Adjuvant immunotherapy of feline fibrosarcoma with recombinant feline interferon-ω. Journal of Veterinary Internal Medicine 2007, 21:1340-1346.
16. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, Ghivizzani SC, Ignatova TN, Steindler DA. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 2005, 7:967-976.
17. Ferguson PJ, Phillips JR, Selner M, Cass CE. Differential activity of vincristine and vinblastine against cultured cells. Cancer Research 1984, 44:3307-3312.
18. Hahn KA, Frazier DL, Cox SK, Legendre AM. Effect of infusion regime on doxorubicin pharmacokinetics in the cat. Journal of The American Animal Hospital Association 1997, 33:427-433.
19. Kochevar DT, Middendorf DL, Mealey KL, Meyers RO, Rogers KS, Barton CL, Habron L, Alberts DS, Polzer JP. Pharmacokinetics and haematological effects of a single intravenous dose of mitoxantrone in cats. Journal of Veterinary Pharmacology and Therapeutics 1995, 18:471-475.
20. Lu K, Savaraj N, Loo TL. Pharmacological disposition of 1,4-dihydroxy-5-8-bis[[2 [(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride in the dog. Cancer Chemotherapy and Pharmacology 1984, 13:63-66.
21. P'eng FK, Wu CW, Chang TJ, Lui WY. Adriamycin concentration in peri130 pheral blood and gastric stump (post-Billroth II gastrectomy) in the dog. Cancer Chemotherapy and Pharmacology 1989, 23:363-366.
22. Ueda Y, Sakurai T, Kasama K, Satoh Y, Atsumi K, Hanawa S, Uchino T, Yanai A. Pharmacokinetic properties of recombinant feline interferon and its stimulatory effect on 2′,5′-Olidoadenylate synthetase activity in the cat. The Journal of Veterinary Medical Science 1993, 55:1-6.
23. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Research 1990, 50:3473-3486.
24. Kataoka T, Oh-hashi F, Sakurai Y, Ida N. Characteristics of in vitro antiproliferation activity of human interferon-β. Cancer Chemotherapy and Pharmacology 1993, 9:75-80.
25. Kubes M, Fuchsberger N, Kontsek P. Cross-species antiviral and antiproliferative activity of human interferon-omega. Journal of Interferon Research 1994, 14:57-59.
26. Chou T. Drug combinations: from laboratory to practice. The Journal of Laboratory and Clinical Medicine 1998, 131:6-8.
27. Arbaje YM, Bittner G, Yingling JM, Storer B, Schiller JH. Antiproliferative effects of interferon-α and -β in combination with 5-fluouracil, cisplatin and Cis- and Trans-retinoic acid in three human lung carcinoma cell lines. Journal of Interferon Research 1993, 13:25-32.
28. Miracco C, Maellaro E, Pacenti L, Del Bello B, Valentini MA, Rubegni P, Pirtoli L, Volpi C, Santopietro R, Tosi P. Evaluation of MDR1, LRP, MRP, and topoisomerase II alpha gene mRNA transcripts before and after interferon-alpha, and correlation with the mRNA expression level of the telomerase subunits hTERT and TEP1 in five unselected human melanoma cell lines. International Journal of Oncology 2003, 23:213-220.
29. Latuzka JR. Genetic toxicity of cytokines. Mutation Research 1996, 361:95-105.
30. Adolf GR. Human interferon omega: a review. Multiple Sclerosis 1995, 1:S44-S47.
31. Horton HM, Hernandez P, Parker SE, Barnhart KM. Antitumor effects of Interferon-ω: in vivo therapy of human tumor xenografts in nude mice. Cancer Research 1999, 59:4064-4068.